Cargando…

The mechanistic basis of protection by non-neutralizing anti-alphavirus antibodies

Although neutralizing monoclonal antibodies (mAbs) against epitopes within the alphavirus E2 protein can protect against infection, the functional significance of non-neutralizing mAbs is poorly understood. Here, we evaluate the activity of 13 non-neutralizing mAbs against Mayaro virus (MAYV), an em...

Descripción completa

Detalles Bibliográficos
Autores principales: Earnest, James T., Holmes, Autumn C., Basore, Katherine, Mack, Matthias, Fremont, Daved H., Diamond, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055377/
https://www.ncbi.nlm.nih.gov/pubmed/33826892
http://dx.doi.org/10.1016/j.celrep.2021.108962
_version_ 1783680436524810240
author Earnest, James T.
Holmes, Autumn C.
Basore, Katherine
Mack, Matthias
Fremont, Daved H.
Diamond, Michael S.
author_facet Earnest, James T.
Holmes, Autumn C.
Basore, Katherine
Mack, Matthias
Fremont, Daved H.
Diamond, Michael S.
author_sort Earnest, James T.
collection PubMed
description Although neutralizing monoclonal antibodies (mAbs) against epitopes within the alphavirus E2 protein can protect against infection, the functional significance of non-neutralizing mAbs is poorly understood. Here, we evaluate the activity of 13 non-neutralizing mAbs against Mayaro virus (MAYV), an emerging arthritogenic alphavirus. These mAbs bind to the MAYV virion and surface of infected cells but fail to neutralize infection in cell culture. Mapping studies identify six mAb binding groups that localize to discrete epitopes within or adjacent to the A domain of the E2 glycoprotein. Remarkably, passive transfer of non-neutralizing mAbs protects against MAYV infection and disease in mice, and their efficacy requires Fc effector functions. Monocytes mediate the protection of non-neutralizing mAbs in vivo, as Fcγ-receptor-expressing myeloid cells facilitate the binding, uptake, and clearance of MAYV without antibody-dependent enhancement of infection. Humoral protection against alphaviruses likely reflects contributions from non-neutralizing antibodies through Fc-dependent mechanisms that accelerate viral clearance.
format Online
Article
Text
id pubmed-8055377
institution National Center for Biotechnology Information
language English
publishDate 2021
record_format MEDLINE/PubMed
spelling pubmed-80553772021-04-19 The mechanistic basis of protection by non-neutralizing anti-alphavirus antibodies Earnest, James T. Holmes, Autumn C. Basore, Katherine Mack, Matthias Fremont, Daved H. Diamond, Michael S. Cell Rep Article Although neutralizing monoclonal antibodies (mAbs) against epitopes within the alphavirus E2 protein can protect against infection, the functional significance of non-neutralizing mAbs is poorly understood. Here, we evaluate the activity of 13 non-neutralizing mAbs against Mayaro virus (MAYV), an emerging arthritogenic alphavirus. These mAbs bind to the MAYV virion and surface of infected cells but fail to neutralize infection in cell culture. Mapping studies identify six mAb binding groups that localize to discrete epitopes within or adjacent to the A domain of the E2 glycoprotein. Remarkably, passive transfer of non-neutralizing mAbs protects against MAYV infection and disease in mice, and their efficacy requires Fc effector functions. Monocytes mediate the protection of non-neutralizing mAbs in vivo, as Fcγ-receptor-expressing myeloid cells facilitate the binding, uptake, and clearance of MAYV without antibody-dependent enhancement of infection. Humoral protection against alphaviruses likely reflects contributions from non-neutralizing antibodies through Fc-dependent mechanisms that accelerate viral clearance. 2021-04-06 /pmc/articles/PMC8055377/ /pubmed/33826892 http://dx.doi.org/10.1016/j.celrep.2021.108962 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Article
Earnest, James T.
Holmes, Autumn C.
Basore, Katherine
Mack, Matthias
Fremont, Daved H.
Diamond, Michael S.
The mechanistic basis of protection by non-neutralizing anti-alphavirus antibodies
title The mechanistic basis of protection by non-neutralizing anti-alphavirus antibodies
title_full The mechanistic basis of protection by non-neutralizing anti-alphavirus antibodies
title_fullStr The mechanistic basis of protection by non-neutralizing anti-alphavirus antibodies
title_full_unstemmed The mechanistic basis of protection by non-neutralizing anti-alphavirus antibodies
title_short The mechanistic basis of protection by non-neutralizing anti-alphavirus antibodies
title_sort mechanistic basis of protection by non-neutralizing anti-alphavirus antibodies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055377/
https://www.ncbi.nlm.nih.gov/pubmed/33826892
http://dx.doi.org/10.1016/j.celrep.2021.108962
work_keys_str_mv AT earnestjamest themechanisticbasisofprotectionbynonneutralizingantialphavirusantibodies
AT holmesautumnc themechanisticbasisofprotectionbynonneutralizingantialphavirusantibodies
AT basorekatherine themechanisticbasisofprotectionbynonneutralizingantialphavirusantibodies
AT mackmatthias themechanisticbasisofprotectionbynonneutralizingantialphavirusantibodies
AT fremontdavedh themechanisticbasisofprotectionbynonneutralizingantialphavirusantibodies
AT diamondmichaels themechanisticbasisofprotectionbynonneutralizingantialphavirusantibodies
AT earnestjamest mechanisticbasisofprotectionbynonneutralizingantialphavirusantibodies
AT holmesautumnc mechanisticbasisofprotectionbynonneutralizingantialphavirusantibodies
AT basorekatherine mechanisticbasisofprotectionbynonneutralizingantialphavirusantibodies
AT mackmatthias mechanisticbasisofprotectionbynonneutralizingantialphavirusantibodies
AT fremontdavedh mechanisticbasisofprotectionbynonneutralizingantialphavirusantibodies
AT diamondmichaels mechanisticbasisofprotectionbynonneutralizingantialphavirusantibodies